Breztri Shortage: What Providers and Prescribers Need to Know in 2026

As of 2026, Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) remains a cornerstone of triple-therapy COPD management, and its newly approved asthma indication expands its clinical relevance substantially. But providers are increasingly hearing from patients who cannot fill their Breztri prescriptions — whether due to localized stock gaps, insurance barriers, or cost issues. This guide is designed to help clinicians navigate these challenges effectively.

Current Breztri Supply Status: Clinical Context

Breztri Aerosphere is not on the FDA Drug Shortage Database in 2026. AstraZeneca reports no manufacturing shortage. However, several market dynamics create real-world access barriers for patients that clinicians need to understand and address proactively:

Demand spike from asthma approval: The April 2026 FDA approval of Breztri for asthma in patients 12 and older has significantly increased prescriptions. Distribution systems have not fully adjusted, causing sporadic stock gaps at the pharmacy level.

Single-source supply: No generic is available. AstraZeneca is the only manufacturer worldwide. Any disruption in production or distribution creates bottlenecks with no fallback supplier.

Insurance gatekeeping: Prior authorization and step therapy requirements are among the most common access barriers. Most payers require documented failure of dual-therapy (ICS/LABA or LAMA/LABA) before approving Breztri. New asthma patients may face additional step therapy hurdles.

Cost barriers: Retail cash price ranges from $670 to $930 per inhaler (30-day supply). Medicare beneficiaries cannot use AstraZeneca's commercial copay programs, leaving some on fixed incomes without affordable access.

Clinical Efficacy Summary: Why Triple Therapy Matters

The clinical rationale for triple therapy is well-established. In the pivotal ETHOS trial (52 weeks, 8,588 subjects), Breztri Aerosphere significantly reduced the annual rate of moderate or severe COPD exacerbations:

24% reduction vs. LAMA/LABA (rate ratio 0.76; P<0.0001)

13% reduction vs. ICS/LABA (rate ratio 0.87; P=0.0027)

FEV1 improvement within 5 minutes on Day 1 (175 mL improvement)

These data support stepped escalation to triple therapy for symptomatic COPD patients with a history of exacerbations who are inadequately controlled on dual therapy. Breztri is FDA-indicated for COPD maintenance and (as of April 2026) asthma maintenance in patients 12 and older.

Navigating Prior Authorization for Breztri in 2026

Prior authorization is the most common barrier. To improve approval rates and turnaround time, ensure your prior auth submissions include:

Documentation of COPD diagnosis (spirometry with post-bronchodilator FEV1/FVC < 0.70 and FEV1 < predicted normal)

History of exacerbations in the prior 12 months (moderate or severe)

Prior use and failure or inadequate response to ICS/LABA and/or LAMA/LABA dual therapy

Blood eosinophil count where available (elevated eosinophils predict greater ICS response)

For asthma patients, documentation should include inadequate control on ICS/LABA dual therapy, airflow obstruction metrics, and exacerbation history. For expedited appeals or peer-to-peer reviews, reference the ETHOS and KRONOS trial data.

Clinical Alternatives When Breztri Is Unavailable

If a patient cannot access Breztri (stock issue, insurance denial, or cost barrier), the following alternatives maintain therapeutic intent:

Trelegy Ellipta (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg): The only other FDA-approved fixed-dose triple combination. Once-daily DPI. GOLD-endorsed as a maintenance option. May be on a different insurance tier than Breztri.

Generic budesonide/formoterol (generic Symbicort) + tiotropium (Spiriva): An affordable two-inhaler triple therapy. Generic Symbicort can cost $50–$150 per month, making this a practical option for uninsured or underinsured patients.

Breo Ellipta + Incruse Ellipta: ICS/LABA (fluticasone/vilanterol) plus LAMA (umeclidinium) in the same Ellipta device family. Once-daily DPI approach with familiarity advantage for patients already on the Ellipta platform.

Patient Assistance Resources to Communicate to Patients

Breztri Zero Pay: For commercially insured patients, AstraZeneca's Zero Pay program may reduce copay to $0. Patients can apply online at breztri.com. Excludes Medicare/Medicaid.

AZ&Me Patient Assistance: Uninsured or Medicare patients meeting income criteria may qualify for free medication. Call 1-800-292-6363.

medfinder: Advise patients who are having trouble locating stock to use medfinder.com/providers, which calls local pharmacies on their behalf and texts them results.

Key Safety Reminders for Prescribers

Breztri is not a rescue inhaler. All patients should be co-prescribed a short-acting beta-2 agonist (SABA), typically albuterol, for acute symptoms.

Avoid concurrent use with other LABA-containing medications or anticholinergics due to additive risk.

Monitor patients on strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) for increased systemic budesonide exposure.

Counsel patients to rinse mouth with water and spit after each dose to reduce oropharyngeal candidiasis risk.

For more resources on helping your patients access difficult-to-find medications, visit medfinder for providers.